Angelo Amabile

1.5k total citations
10 papers, 905 citations indexed

About

Angelo Amabile is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Angelo Amabile has authored 10 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Immunology and 2 papers in Oncology. Recurrent topics in Angelo Amabile's work include Epigenetics and DNA Methylation (3 papers), RNA modifications and cancer (2 papers) and CRISPR and Genetic Engineering (2 papers). Angelo Amabile is often cited by papers focused on Epigenetics and DNA Methylation (3 papers), RNA modifications and cancer (2 papers) and CRISPR and Genetic Engineering (2 papers). Angelo Amabile collaborates with scholars based in United States, Italy and Germany. Angelo Amabile's co-authors include Angelo Lombardo, Davide Cittaro, Luigi Naldini, Mauro Biffi, Alessandro Migliara, Paola Capasso, Luca Zammataro, Óscar M. Pello, Maria De Pizzol and Andrea Doni and has published in prestigious journals such as Cell, Nature Communications and Blood.

In The Last Decade

Angelo Amabile

9 papers receiving 894 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angelo Amabile United States 7 564 263 120 106 95 10 905
Kirsten Canté-Barrett Netherlands 17 529 0.9× 346 1.3× 221 1.8× 86 0.8× 46 0.5× 33 1.1k
Chi Yan United States 18 385 0.7× 199 0.8× 310 2.6× 64 0.6× 41 0.4× 43 805
Jiyung Shin United States 10 997 1.8× 137 0.5× 93 0.8× 129 1.2× 42 0.4× 11 1.4k
Clemens Hofmann Germany 10 392 0.7× 157 0.6× 190 1.6× 43 0.4× 59 0.6× 13 718
Zee‐Fen Chang Taiwan 17 553 1.0× 130 0.5× 144 1.2× 40 0.4× 21 0.2× 26 857
Lutz Zeitlmann Germany 12 563 1.0× 332 1.3× 96 0.8× 63 0.6× 45 0.5× 15 1.1k
Jae Ryoung Hwang South Korea 16 686 1.2× 116 0.4× 95 0.8× 63 0.6× 16 0.2× 33 975
Gabriella Forte United Kingdom 13 530 0.9× 94 0.4× 145 1.2× 56 0.5× 19 0.2× 16 741
Eric Flatter France 13 869 1.5× 201 0.8× 338 2.8× 168 1.6× 20 0.2× 16 1.1k
Xia Huang China 5 617 1.1× 104 0.4× 66 0.6× 91 0.9× 13 0.1× 10 759

Countries citing papers authored by Angelo Amabile

Since Specialization
Citations

This map shows the geographic impact of Angelo Amabile's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Amabile with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Amabile more than expected).

Fields of papers citing papers by Angelo Amabile

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo Amabile. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Amabile. The network helps show where Angelo Amabile may publish in the future.

Co-authorship network of co-authors of Angelo Amabile

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo Amabile. A scholar is included among the top collaborators of Angelo Amabile based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo Amabile. Angelo Amabile is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Laudier, Damien M., et al.. (2025). WNT7A mRNA Lipid Nanoparticles Promote Muscle Hypertrophy and Reduce Fatty Infiltration. Cellular and Molecular Bioengineering. 18(5). 387–401.
2.
Mollaoglu, Gürkan, Alexander Tepper, Chiara Falcomatà, et al.. (2024). Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 187(26). 7492–7510.e22. 33 indexed citations
3.
Baccega, Tania, S. Torchio, Silvia Pellegrini, et al.. (2022). Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I−/− iPSCs for β cell replacement. Cell Reports. 40(13). 111423–111423. 19 indexed citations
4.
Adamopoulos, Christos, Tamer A. Ahmed, Maxwell R. Tucker, et al.. (2021). Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery. 11(7). 1716–1735. 40 indexed citations
5.
Frenquelli, Michela, Elisa Barbieri, Anna De Antoni, et al.. (2021). Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene. Life Science Alliance. 4(8). e202101019–e202101019. 2 indexed citations
6.
Rosato, Anna Scotto, Sandro Montefusco, Chiara Soldati, et al.. (2019). TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway. Nature Communications. 10(1). 5630–5630. 139 indexed citations
7.
Amabile, Angelo, Alessandro Migliara, Paola Capasso, et al.. (2016). Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell. 167(1). 219–232.e14. 351 indexed citations
8.
Amabile, Angelo, Alessandro Migliara, Paola Capasso, et al.. (2016). 729. Inheritable Silencing of Endogenous Gene by Hit-and-Run Targeted Epigenetic Editing. Molecular Therapy. 24. S287–S288. 1 indexed citations
9.
Tonti, Elena, Nereida Jiménez de Oya, E. Ashley Moseman, et al.. (2013). Bisphosphonates Target B Cells to Enhance Humoral Immune Responses. Cell Reports. 5(2). 323–330. 32 indexed citations
10.
Pello, Óscar M., Maria De Pizzol, Massimiliano Mirolo, et al.. (2011). Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood. 119(2). 411–421. 288 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kirsten Canté-Barrett Breakdown of academic impact, for papers by Chi Yan Breakdown of academic impact, for papers by Jiyung Shin Breakdown of academic impact, for papers by Clemens Hofmann Breakdown of academic impact, for papers by Zee‐Fen Chang Breakdown of academic impact, for papers by Lutz Zeitlmann Breakdown of academic impact, for papers by Jae Ryoung Hwang Breakdown of academic impact, for papers by Gabriella Forte Breakdown of academic impact, for papers by Eric Flatter Breakdown of academic impact, for papers by Xia Huang
Rankless by CCL
2026